NCT05716919View on ClinicalTrials.gov

Multiple Ascending Dose Study of CG200745 'Ivaltinostat' Oral Capsule

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

March 9, 2023

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2023

Conditions
Hematologic MalignancySolid TumorFibrosis
Interventions
DRUG

Ivaltinostat

Ivaltinostat capsule

OTHER

Placebo

Placebo capsule

Trial Locations (1)

Unknown

Seoul National University Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Machaon Biotherapeutics, Inc.

INDUSTRY